Fran Rawlins

TRANSFORM Study Manager - Imperial Prostate | Medical Research | Former GB Rowing Team Athlete

[Hashim U. Ahmed @LondonProstate1]

📣The £42M TRANSFORM study will get a £20M boost so that all eligible Black men are invited to join stage 2

📶Policies on healthcare for any group to be based on evidence

🇬🇧Govt also funding wider access to focal prostate therapy to ⬇️ harms of surgery & radiotherapy

[Hashim U. Ahmed @LondonProstate1]

📣The £42M TRANSFORM study will get a £20M boost so that all eligible Black men are invited to join stage 2

📶Policies on healthcare for any group to be based on evidence

🇬🇧Govt also funding wider access to focal prostate therapy to ⬇️ harms of surgery & radiotherapy

[Imperial Prostate @IP_London]

We had an amazing day at the London Landmarks Half Marathon yesterday! 🏃🏽‍♀️🏃🏽‍♂️

The @IP_London Run Club was proud to support @prost8uk!

We’re so close to our fundraising goal - help us get over the line!: https://t.co/j5A1H2F39G

Thank you for all the support! ❤️💙

[Imperial Prostate @IP_London]

Meanwhile! Back at in London, @Fran_Rawlins gave a brilliant presentation showcasing TRANSFORM at the @ImperialCTU Unit Meeting 2025 #prostatecancer #prostatescreening

@ImperialSandC @ProstateUK @LondonProstate1

[Imperial NHS 💙 @ImperialNHS]

The trial is led by researchers @ImperialNHS and @imperialcollege with @ucl, @QMUL and @ICR_London.

Backed by @ProstateUK, it is the biggest and most ambitious prostate cancer trial in 20 years that aims to transform diagnosis and reduce prostate cancer deaths by up to 40%.

2/2

[Imperial NHS 💙 @ImperialNHS]

Prostate cancer is now the most commonly diagnosed cancer in England according to an analysis by @ProstateUK.

This #WorldCancerDay, we want to shine a light on the TRANSFORM trial which is looking to find the best way to screen for prostate cancer ➡️ https://t.co/StknliQEkh

1/2

[Hashim U. Ahmed @LondonProstate1]

Fine balance of savings lives & harms of screening for prostate cancer

“…we have not shown enough risk mitigation yet to justify a national screening programme.”

Which is why @ProstateUK & @NIHRresearch funded £42M TRANSFORM study

https://t.co/Ve5Jfyy6lb

[Imperial Prostate @IP_London]

Congratulations #IP7PACIFIC - 8️⃣6️⃣5️⃣ patients recruited so far!

⏱️ Evaluating the role of biparametric MRI & image-fusion targeted biopsies to detect prostate cancer

🔗 https://t.co/bZwzpHEelK

#UrSoMe #prostatecancer #prostatecancerdiagnosis #bpMRI

[ProstateUK Profs @ProstateUKProfs]

[7/7] Prostate Cancer UK are proud to have launched the £42m TRANSFORM trial to find the best way to screen for prostate cancer, so one day all men at risk are invited for regular tests to find aggressive prostate cancer in time for a cure.

https://t.co/wGNYIVvLzc

[Antony Smith 🇬🇧 🏴󠁧󠁢󠁥󠁮󠁧󠁿 @smithmaestro]

It’s a complete disgrace. There has to be accountability. This is daily. Who is actually listening to this @thameswater @LondonPortAuth @LBC

[Imperial College London @imperialcollege]

We're proud to announce that #OurImperial Professor Hashim Ahmed [@LondonProstate1] and Professor Rakesh Heer are two of the six lead researchers on @ProstateCancerUK's £42 million TRANSFORM screening trial.

TRANSFORM is the biggest and most ambitious prostate cancer trial in 20 years that aims to transform diagnosis and save thousands more lives each year.

https://t.co/otpDbJxoeE

[Imperial Prostate @IP_London]

We are ✨incredibly proud✨ to be leading the #TRANSFORM prostate cancer screening trial in collaboration with our colleagues from @ucl @QMUL @ICR_London @royalmarsdenNHS @imperialcollege supported by @ProstateUK @NIHRresearch @MovemberUK

[Hashim U. Ahmed @LondonProstate1]

Well done everyone. What a team! Very proud of every single one of them. #ipmasterclass24

[Imperial Prostate @IP_London]

Thanks to our enthusiastic chairs @AJWLight and Mr Arnas Rakauskas.

Onto our final plenary session of Day 1: Prostate Biopsy, chaired by @johannboaz and @Fran_Rawlins.

[Surgery and Cancer @ImperialSandC]

🧵@ImperialNHS has been awarded £3m by @NIHRresearch for a new HealthTech Research Centre, led by S&C's @profgeorgehanna, to support the development & evaluation of new diagnostic innovations for cancer, infectious & respiratory diseases, critical care, & primary and social care.

[Imperial Prostate @IP_London]

🎉 What a fantastic way to end the year at the @ImperialSandC Awards!

Congratulations to everyone at @IP_London for their dedication and hard work in 2023!

@imperialurology @imperialcollege @ImperialNHS

[Imperial Prostate @IP_London]

Team @IP_London at #BAUS23!

@LondonProstate1 @TaimurShah @Connor_Urol @Fran_Rawlins @NikhilMayor @AJWLight

[Imperial Prostate @IP_London]

🔬 Tomorrow (20/05) is #InternationalClinicalTrialsDay

🔬 Thank you to our hard working multi-disciplinary research team - and most importantly our patient participants!

🔬 Take a look at #ImperialProstate clinical trials past & present @ https://t.co/wcuHaBDVcC

[Dr Heminder Kaur Sokhi @HemmySokhi]

Great milestone! This RCT will answer the key question of mpMRI vs bpMRI for prostate cancer detection

@LondonProstate1 @ProfPadhani @andrea_rockall @Heer_Lab

[Hashim U. Ahmed @LondonProstate1]

I hear at 30 now!

Whilst paired cohort studies might show non-inferiority, how will radiologists score, and urologists use, a biparametric MRI when that’s all they have?

#IP7PACIFIC is the only pivotal non-inferiority RCT of bpMRI vs. mpMRI